144 related articles for article (PubMed ID: 14534331)
41. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients.
Piccaluga PP; Malagola M; Amabile M; Rondoni M; Paolini S; Pane F; Russo D; Visani G; Baccarani M; Martinelli G
Haematologica; 2004 Oct; 89(10):1269-71. PubMed ID: 15477218
[TBL] [Abstract][Full Text] [Related]
42. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
43. Trisomy 8 finding treatment of imatinib mesylate in chronic myeloid leukemia cases.
Tunca Y; Güran S
Exp Hematol; 2005 Feb; 33(2):151. PubMed ID: 15676207
[No Abstract] [Full Text] [Related]
44. Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate.
Kubota Y; Waki M
Cancer Genet Cytogenet; 2010 Sep; 201(2):135-6. PubMed ID: 20682400
[No Abstract] [Full Text] [Related]
45. Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now.
Mauro MJ
Haematologica; 2005 Mar; 90(3):291B. PubMed ID: 15749655
[No Abstract] [Full Text] [Related]
46. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
[TBL] [Abstract][Full Text] [Related]
47. [Chronic myeloid leukemia--treatment].
Stoetzer OJ; Hentrich M; Salat C
Dtsch Med Wochenschr; 2002 Dec; 127(49):2621-4. PubMed ID: 12469275
[No Abstract] [Full Text] [Related]
48. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
49. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
Alimena G; Breccia M; Luciano L; Quarantelli F; Diverio D; Izzo B; De Angelis B; Mancini M; Latagliata R; Carmosino I; Nanni M; Picardi M; Rotoli B; Mandelli F; Pane F
Leuk Res; 2008 Feb; 32(2):255-61. PubMed ID: 17692911
[TBL] [Abstract][Full Text] [Related]
50. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
Colla S; Sammarelli G; Voltolini S; Crugnola M; Sebastio P; Giuliani N
Haematologica; 2004 May; 89(5):611-3. PubMed ID: 15136228
[TBL] [Abstract][Full Text] [Related]
51. The role of alpha-interferon in chronic myelogenous leukaemia in Imatinib era.
Franceschini R; Zoppi F; Garuti A; Gobbi M
J Exp Clin Cancer Res; 2004 Dec; 23(4):697-8. PubMed ID: 15743042
[No Abstract] [Full Text] [Related]
52. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
53. Not so NICE for CML.
Goldman J; Apperley J; Clark R; Green T; Holyoake T; O'Brien S; Shepherd P
Lancet; 2002 Jun; 359(9322):2036. PubMed ID: 12076575
[No Abstract] [Full Text] [Related]
54. Chronic myeloid leukemia.
Sawyers CL
N Engl J Med; 1999 Apr; 340(17):1330-40. PubMed ID: 10219069
[No Abstract] [Full Text] [Related]
55. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.
Campiotti L; Appio L; Solbiati F; Ageno W; Venco A
Leuk Res; 2009 Nov; 33(11):e212-3. PubMed ID: 19589593
[No Abstract] [Full Text] [Related]
56. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
Bonifacio M; Binotto G; Calistri E; Maino E; Tiribelli M;
Ann Hematol; 2014 Jan; 93(1):163-4. PubMed ID: 24292539
[No Abstract] [Full Text] [Related]
57. Leukemia cells fall on their swords.
Rutherford A
Trends Mol Med; 2001 Apr; 7(4):149. PubMed ID: 11286930
[No Abstract] [Full Text] [Related]
58. Occurrence of BCR-ABL1-positive chronic myeloid leukemia following essential thrombocythemia.
Weng WH; Shih LY
Acta Haematol; 2011; 126(4):220-3. PubMed ID: 21934297
[No Abstract] [Full Text] [Related]
59. Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia.
Bocchia M; Abruzzese E; Forconi F; Ippoliti M; Trawinska MM; Pirrotta MT; Raspadori D; Tozzi M; Gozzetti A; Lauria F
Leukemia; 2006 Jan; 20(1):142-3. PubMed ID: 16281064
[No Abstract] [Full Text] [Related]
60. [Further improving the standard of treatment for chronic myeloid leukemia].
Pu Q
Zhonghua Nei Ke Za Zhi; 2006 May; 45(5):353-4. PubMed ID: 16780730
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
